| http://www.w3.org/ns/prov#value | - This study is a placebo-controlled, double blind trial evaluating the efficacy, safety and pharmacokinetics of intravenously administered OCR-002 reducing the severity of HE symptoms in hospitalized patients with liver cirrhosis and an acute episode of HE. Acute HE remains a serious neurological disorder with few treatment options, said Linda Grais, M.D., chief executive officer of Ocera.
|
